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Abstract 26 
 27 
There are indications of overtreatment in older type 2 diabetes patients in both the 28 
US and Europe. We assessed the level of personalized diabetes treatment for older 29 
patients in primary care, focusing on overtreatment.  30 
Based on Dutch guidelines individuals ≥ 70 years were classified into three HbA1c 31 
treatment target groups: 7% (53 mmol/mol), 7.5% (58 mmol/mol) and 8% (64 32 
mmol/mol).   33 
In our cohort of 1.002 patients (n=319 ≥ 70 yrs), the 165 patients with target above 34 
7% had more micro- and macrovascular complications, used more often ≥ 5 35 
medicines and were more often frail compared to those with an HbA1c target ≤ 7%. 36 
Of these 165 patients 64 (38.8%) were overtreated, i.e. 20% of all people ≥ 70 years. 37 
The majority of overtreated people were frail and used ≥ 5 medicines. Hypoglycemia 38 
occurred in 20.3% of these patients and almost 30% reported fall accidents.  39 
Personalized treatment in older people with type 2 diabetes is no common practice.  40 
A substantial number of older people are overtreated, with likely harmful 41 
consequences. To prevent overtreatment, definition of lower HbA1C limits might be 42 
helpful.  43 
 44 
 45 
 46 
 47 
 48 
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 49 
Introduction 50 
Beneficial effects of stringent HbA1c goals in older patients with long existing type 2 51 
diabetes and vascular complications are not proven. On the contrary, older patients 52 
are at higher risk of developing hypoglycemia because of reduced food intake and 53 
wrong medication usage. Hypoglycemia is associated with adverse effects like low 54 
health-related quality of life, development of dementia, cardiovascular disease, falls 55 
and even increased mortality. Overall, the risk of harm associated with an HbA1c 56 
target lower than the conventional 7% (53 mmol/mol) seems to outweigh the possible 57 
benefits for adults of 70 years and older. The American Diabetes Association (ADA) 58 
provides a framework for considering treatment goals for glycemia, with reasonable 59 
HbA1c goals ranging from < 7.5% (58 mmol/mol) to < 8.5% (69 mmol/mol). 1  60 
In 2013, the Dutch College of General practitioners published guidelines, based on 61 
results of the ACCORD, ADVANCE and VADT trials, with an algorithm to put 62 
personalized hyperglycemia treatment into practice. With this algorithm, the 63 
personalized HbA1c target can be determined based on the patient’s age, the 64 
intensity of diabetes treatment and the known diabetes duration. 2 According to this 65 
algorithm patients aged ≥ 70 years treated with a lifestyle advice only or with 66 
metformin monotherapy should achieve an HbA1c target ≤ 7% (53 mmol/mol). 67 
Patients above 70 years who are using more blood glucose lowering agents than 68 
metformin only and with a diabetes duration less than 10 years should achieve an 69 
HbA1c ≤ 7.5% (58 mmol/mol) and those with a diabetes duration above 10 years 70 
have a target ≤ 8% (64 mmol/mol). In the Netherlands, about 85% of people with type 71 
2 diabetes are treated in the primary care setting. Most recent data (2013) from a 72 
nationwide primary care database provide proportions of type 2 diabetes patients in 73 
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primary care < 70 years with an HbA1c < 7% (53 mmol/mol) and an HbA1c > 8.5% 74 
(69 mmol/mol). 3 However, these percentages do not provide insight into the level of 75 
personalized hyperglycemia treatment. In the US and Europe there are indications of 76 
overtreatment in older type 2 diabetes patients, both in patients with and without pre-77 
existing vascular complications. 4–6 We aimed to assess the level of the personalized 78 
diabetes treatment for older patients in primary care, focusing on overtreatment.  79 
 80 
METHODS 81 
Study design and setting 82 
Data for this observational study (study period January 1th – December 31th 2016) 83 
were extracted from the electronic patient records in March 2017 in five primary care 84 
centers of the Leidsche Rijn Julius Health Centers. People were excluded when they 85 
were treated for their diabetes by a medical specialist (n=165), refused diabetes care 86 
(n=37) or did not show up for monitoring visits during the observation period (n=66), 87 
resulting in 1.002 patients with type 2 diabetes included in the study.  88 
Data collection and variables  89 
Patient characteristics, macrovascular- and microvascular complications and  90 
comorbidities were all retrieved from the electronic medical records in March 2017,  91 
as well as medication use. We defined polypharmacy as the prescription of at least 92 
five medications per patient. A person’s frailty was determined by the validated Frailty 93 
Index (FI). 7 In this study, patients with a FI score >0.2 were considered frail.  94 
Data on hypoglycemia, emergency room visits and fall accidents were manually 95 
retrieved from the electronic medical records in patients who were classified as 96 
overtreated. Hypoglycemia was considered present when patient’s complaints due to 97 
a low blood glucose level had been recorded.  98 
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Personalized Hba1c targets: on target, overtreatment and undertreatment 99 
According to the algorithm from the Dutch guidelines (Supplementary Appendix, 100 
Figure 1) older individuals, i.e.  ≥ 70 years, could be classified in different subgroups 101 
with the accompanying HbA1c target. Based on the differential targets, we defined 102 
‘on target’, ‘overtreated’ and ‘undertreated’ as follows: If target  ≤ 7% (53 mmol/mol): 103 
no lower limit available for overtreatment, on target if HbA1c  ≤ 7% (53 mmol/mol), 104 
undertreated if HbA1c > 7% (53 mmol/mol); if target  ≤7.5% (58 mmol/mol): 105 
overtreated if HbA1c ≤ 7% (53 mmol/mol), on target if HbA1c > 7% (53 mmol/mol) 106 
but ≤ 7.5% (58 mmol/mol), undertreated if HbA1c >7.5% (58 mmol/mol); if target  ≤ 107 
8% (64 mmol/mol): overtreated if  HbA1c ≤ 7% (53 mmol/mol), on target if  HbA1c 108 
>7% (53 mmol/mol) but ≤ 8% (64 mmol/mol), undertreated if HbA1c >8% (64 109 
mmol/mol). 110 
Statistical Analyzes 111 
Patients on their personalized treatment targets were compared to those not on 112 
treatment target using Chi-square, Mann Whitney U and Kruskal Wallis tests (IBM 113 
SPSS statistics 24). 114 
 115 
RESULTS 116 
In the cohort the mean age was 62.8 (12.2) years, with 54.1% men and a median 117 
diabetes duration of 7.0 years (36.2% ≥10 years). The median HbA1c was 6.9% (52 118 
mmol/mol), 20.3% of the patients had macrovascular complications and 38.2% had 119 
microvascular complications. Of the 1.002 patients, 319 (31.8%) patients were ≥ 70 120 
years with 51.7% men and a median diabetes duration of 10 years. Their median 121 
HbA1c was 7.0% (53.3 mmol/mol), 30.1% had macrovascular complications and 122 
50.8% had microvascular complications. One in five people ≥ 70 years used insulin 123 
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and almost 70% in this age category used at least five medications (Supplementary 124 
Table). Using the algorithm from the Dutch guidelines, 165 people could be classified 125 
in the subgroup with an HbA1c  target > 7% (53 mmol/mol) (Figure 1, Suppl. 126 
Appendix). Their median HbA1c was 7.3% (56 mmol/mol, IQR 15) versus 6.8% (51 127 
mmol/mol, IQR 12) in the group with an HbA1c target ≤ 7% (53 mmol/mol) (p<0.05).  128 
Those with an HbA1c  target > 7% (53 mmol/mol) had more often microvascular 129 
(54.0 % vs 35.2%, p<0.05) and macrovascular complications (33.3% vs 17.7%, p< 130 
0.05). They used more often ≥ 5 medications (87.3% vs 53.2%, p<0.05) and were 131 
more often frail (44.2% vs 13.9%, p<0.05) than people with an HbA1c target ≤ 7% 132 
(53 mmol/mol).  133 
Fifty three individuals were categorized in the subgroup with HbA1c target ≤ 7.5% (58 134 
mmol/mol) and 112 in the subgroup with target ≤ 8% (64 mmol/mol). In the former 135 
subgroup 13 (24.5%) people were on target, 23 (43.4%) were overtreated and 17 136 
(32.1%) undertreated. In the latter group these proportions were 36.6%, 36.6% and 137 
26.8% respectively.   138 
Table 1 shows the characteristics of people with HbA1c treatment target ≤ 7.5% (58 139 
mmol/mol) and whether they were on target, over- or undertreated. The achieved 140 
HbA1c values between these categories differed significantly, but other 141 
characteristics did not. More than 80% used sulphonylureas, 15 to 35% used insulin 142 
combined with oral blood glucose lowering agents. Almost all people used at least 143 
five medications, almost half of them had comorbidities and one in three were frail. 144 
Table 2 provides similar data from the people with HbA1c treatment target  ≤ 8% (64 145 
mmol/mol). Also in this category achieved HbA1c levels differed significantly between 146 
people on target, those who were over- and undertreated. Individuals who were ‘on 147 
target’ had significantly less microvascular complications compared to those who 148 
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were over- or undertreated (34.1% vs 63.4 % and 66.7%; P<0.05). Surprisingly, 149 
people who were overtreated used less often insulin combined with oral medication 150 
compared to the other two categories (24.4% versus and 43.9% and 63.3%, p<0.05).  151 
 152 
Overtreatment  153 
Overall, 64 people received overtreatment, that means 38.8% of the165 with an 154 
HbA1c  target > 7% (53 mmol/mol). As stated above 23 (43.4%) of people with 155 
HbA1c target ≤ 7.5% (58 mmol/mol) could be categorized as overtreated according to 156 
the evidence based guidelines. They had a median age of 72 years, a median 157 
diabetes duration of 5 years and a medianHbA1c of 6.5% (48 mmol/mol). Five 158 
(21.7%) had an eGFR < 45ml/min. Eight individuals who were overtreated (34.8%) 159 
were living alone and eight (34.8%) were frail. The majority of these overtreated 160 
patients used metformin (78.3%) and/ or sulphonylureas (87.0%). Four (17.4%) of 161 
them experienced hypoglycemia in the observation period, four had a fall accident 162 
and one patient had a hypoglycemia related emergency room visit.  163 
Among the people with an HbA1c target ≤ 8% (64 mmol/mol) more than one in three 164 
(36.6%) patients could be categorized as overtreated. They had a median age of 76 165 
years, a median diabetes duration of 14 years and a median HbA1c of 6.5% (47 166 
mmol/mol). Three (7.3%) had an eGFR< 45 ml/min. Half of the overtreated 167 
individuals could be considered frail and 13 (31.7%) lived alone. The majority used 168 
metformin (82.9%) and/or sulphonylureas (70.7%). In this group, more people used 169 
insulin compared to overtreated individuals with a target ≤ 7.5% (31.7% vs.8.7%). 170 
During the observation period 12 people (29.3%) reported fall accidents, 9 (22%) 171 
reported hypoglycemia and one patient had a hypoglycemia related emergency room 172 
visit. 173 
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 174 
Discussion 175 
This study aimed to assess the level of personalized type 2 diabetes treatment for 176 
older patients in primary care, focusing on overtreatment of these patients. From 319 177 
people  ≥ 70 years, more than one in two should have an HbA1c target > 7% (53 178 
mmol/mol) according to the evidence-based guidelines. Many people who were 179 
overtreated according to the guidelines  had complications, comorbidities, 180 
polypharmacy, can be considered frail and used medication that can cause 181 
hypoglycemia. 182 
Although the Dutch diabetes guidelines are very well implemented in primary care, 183 
without financial incentives to drive HbA1c levels lower, de-intensifying treatment is 184 
not yet common practice, whereas a great number of patients would benefit from it 185 
6,8. Notably, although hypoglycemia and falls were reported and recorded for 186 
overtreated people in our study, their treatment was not de-intensified. Whereas the 187 
number of patients included in this study is small, the results give a clear signal that 188 
overtreatment in older type 2 diabetes patients is a real problem. 189 
Some limitations should be taken into account. First, no data were available of people 190 
who were treated by specialists. Their treatment can be seen as more complex and 191 
on the one hand they are less likely to reach their HbA1c target but on the other hand 192 
many of them are likely to benefit from a less strict HbA1c target. Also people 193 
refusing regular diabetes care could not be included. With these two categories of 194 
patients included, the proportion of people receiving overtreatment would have been 195 
different.   196 
To conclude , almost 40% of older adults with type 2 diabetes and an evidence 197 
based HbA1c target above 7% were overtreated, representing about 20% of all 198 
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adults ≥ 70 years. Also according to the ADA and EASD guidelines they should have 199 
been treated less intensively. Naturally, if a well-informed patient prefers to continue 200 
his or her medication, a shared decision could be to do so. From a medical point of 201 
view such a patient might be called overtreated, but in a person-centered diabetes 202 
care this is acceptable.  203 
Care professionals should leave the ‘one size fits all’ approach and realize the 204 
possible benefits of de-intensifying blood glucose lowering treatment. To prevent 205 
overtreatment, a lower HbA1c limit in the guidelines might be helpful. Diabetes quality 206 
indicators should not be based on population based mean values, because means 207 
will overlook under- and overtreatment completely.  208 
 209 
 210 
  211 
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